Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BeOne Medicines Ltd. - American Depositary Shares (NQ:ONC)

279.68 -8.24 (-2.86%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BeOne Medicines Ltd. - American Depositary Shares

< Previous 1 2 3 4 5 Next >
News headline image
European Commission Approves Tablet Formulation of BeOne Medicines’ BRUKINSA® for All Approved Indications
From BeOne Medicines Ltd.
Via Business Wire
News headline image
Earnings Scheduled For August 8, 2025 ↗
 
Via Benzinga
News headline image
A Glimpse of BeiGene's Earnings Potential ↗
 
Via Benzinga
News headline image
Earnings Scheduled For August 6, 2025 ↗
 
Via Benzinga
News headline image
BeiGene's Earnings: A Preview ↗
 
Via Benzinga
News headline image
BeOne Medicines (ONC) Q2 EPS Soars 924% ↗
Via The Motley Fool
News headline image
BeOne Medicines Announces Second Quarter 2025 Financial Results and Business Updates
From BeOne Medicines Ltd.
Via Business Wire
News headline image
BeOne Medicines Receives PRIME Designation from the European Medicines Agency for BGB-16673 in Waldenstrom’s Macroglobulinemia
From BeOne Medicines Ltd.
Via Business Wire
News headline image
BeOne Medicines Receives Positive CHMP Opinion for TEVIMBRA® in Neoadjuvant/Adjuvant NSCLC Treatment
From BeOne Medicines Ltd.
Via Business Wire
News headline image
Deep Dive Into BeOne Medicines Stock: Analyst Perspectives (9 Ratings) ↗
 
Via Benzinga
News headline image
BeOne Medicines to Announce Second Quarter 2025 Financial Results on August 6
From BeOne Medicines Ltd.
Via Business Wire
News headline image
European Commission Approves TEVIMBRA® in Combination with Chemotherapy as a First-Line Treatment for Nasopharyngeal Carcinoma
From BeOne Medicines Ltd.
Via Business Wire
News headline image
AstraZeneca In $15B Talks For Drug That Could Upend Lung Cancer Treatment ↗
Via Benzinga
News headline image
What 8 Analyst Ratings Have To Say About BeOne Medicines ↗
 
Via Benzinga
News headline image
BeOne Medicines Showcases Groundbreaking Oncology Pipeline at R&D Day
From BeOne Medicines Ltd.
Via Business Wire
News headline image
BeOne Medicines Receives Positive CHMP Opinion for Tablet Formulation of BRUKINSA®
From BeOne Medicines Ltd.
Via Business Wire
News headline image
AppLovin, First Solar And Li Auto Are Among Top 10 Large Cap Losers Last Week (June 16-20): Are The Others In Your Portfolio? ↗
Top 10 worst performing large-cap stocks last week: APP, FSLR, JHX, ONC, GSK, ACN, ANET, LI, CPAY, MA. Reasons include short-sell report, tax bill, and market selloff. 
Via Benzinga
News headline image
CureVac, TELUS International, Oracle And Other Big Stocks Moving Higher On Thursday ↗
 
Via Benzinga
News headline image
BeOne Medicines Showcases Breakthrough Data in CLL and MCL at EHA 2025
From BeOne Medicines Ltd.
Via Business Wire
News headline image
U.S. FDA Approves Tablet Formulation of BeOne’s BRUKINSA® for All Approved Indications
From BeOne Medicines Ltd.
Via Business Wire
News headline image
BeOne Medicines to Host Investor R&D Day Webcast on June 26, 2025
From BeOne Medicines Ltd.
Via Business Wire
News headline image
BeOne Medicines Unveils Promising Clinical Data for Two Novel Breast Cancer Therapies at ASCO 2025
From BeOne Medicines Ltd.
Via Business Wire
News headline image
BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSA’s Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 2025
From BeOne Medicines Ltd.
Via Business Wire
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
BeOne Medicines Launches Following Redomiciliation to Switzerland, Marking a New Chapter in Global Oncology
From BeOne Medicines Ltd.
Via Business Wire
News headline image
BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Nasopharyngeal Cancer
From BeiGene, Ltd.
Via Business Wire
News headline image
BeiGene Presents Pioneering Cancer Research at ASCO 2025 – Redefining Treatment Across Hematology and Solid Tumors
From BeiGene, Ltd.
Via Business Wire
News headline image
Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030 ↗
Via The Motley Fool
Topics Economy Law Enforcement
News headline image
BeiGene Showcases Strength of Hematology Portfolio at EHA 2025 with New Data Highlighting BRUKINSA’s Leadership and Next-Generation Innovation
From BeiGene, Ltd.
Via Business Wire
News headline image
Earnings Scheduled For May 14, 2025 ↗
 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.